RCS - Angle PLC - ANGLE presents two posters at EACR

AngleAnnouncement

13/11/2024 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241113:nRSM9822La&default-theme=true

RNS Number : 9822L  Angle PLC  13 November 2024

 For immediate release  13 November 2024

 

ANGLE plc ("the Company")

 

Parsortix-based assays showcased at the european association for cancer
research liquid biopsies conference

 

Two posters highlight the importance of epitope-independent CTC enrichment and
molecular characterisation of CTCs

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce its participation at
the European Association for Cancer Research (EACR) Liquid Biopsies Conference
being held in Lyon, France from 12 to 14 November 2024.

 

ANGLE presented two posters at the EACR Liquid Biopsies Conference:

 

1.  Combined epitope-independent microfluidic isolation and advanced staining
of circulating tumour cells isolated from metastatic prostate cancer blood
samples

 

This poster presentation reports on the utility of combining ANGLE's
Parsortix(®) system for CTC capture with the Portrait(®)+ CTC staining kit
for CTC detection and phenotypic characterisation. This workflow provides an
efficient, standardised solution for the characterisation of multiple CTC
phenotypes (epithelial, mesenchymal and those transitioning).

 

In a cohort of prostate cancer patients 64% of patients were positive for
CTCs, and CTC clusters, which have up to 100 times increased metastatic
potential, were found in 67% of the CTC positive samples. Patients with only
mesenchymal CTCs accounted for 77% of the CTC positive patients, and no
patients had only epithelial CTCs. This highlights the importance and value of
using an epitope-independent CTC enrichment system, such as the Parsortix
system.

 

This study also demonstrates the potential utility of this workflow for
longitudinal patient monitoring, where changes in CTC number (including their
absence) and phenotype are associated with patient status.  The study
presented two case studies of metastatic prostate cancer patients with CTC
results preceding a change in patient clinical status over time.

 

2.  Enhancing Multiplexing Capabilities in Digital PCR for Circulating Tumour
Cell Analysis Using Amplitude-Based methodology

 

Molecular characterisation of CTCs is particularly important in the metastatic
disease setting, where tissue biopsies may not be possible or repeatable, and
there is a need for real-time tumour analysis and longitudinal monitoring of
disease progression and treatment response. Recent advances in digital PCR
(dPCR) technology, combined with multiplexing capabilities, have enhanced the
ability to perform precise molecular characterisation from even a small number
of CTCs.

 

This proof-of-concept study demonstrates that using amplitude-based
multiplexing with QIAGEN's Qiacuity dPCR system can increase the number of
genes that can be assessed simultaneously in a Parsortix-enriched CTC sample.
This method of molecular characterisation improves the ability to report a
wider range of genetic markers from a single sample with the potential to
provide a more comprehensive view into tumour biology.

 

Chief Scientific Officer, Karen Miller, commented:

"We are pleased to have presented two posters at the EACR Liquid Biopsies
Conference. The results of these studies further demonstrate the utility of
ANGLE's technology for capturing and characterising CTCs at both the cellular
and molecular level. Advances in molecular characterisation will be key to
building a comprehensive picture of cancer and providing insight during
targeted drug discovery and development. We are continuing to develop
Parsortix-based molecular assays to provide a range of highly sensitive and
specific assays to serve the needs of our pharma customers."

 

The posters are available for review at:
https://angleplc.com/resources/posters/
(https://angleplc.com/resources/posters/)

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on clinical services and diagnostic
products. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made assay development
and clinical trial testing for pharma. Products include the Parsortix system,
associated consumables and assays.

 

Over 100 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

 

Any reference to regulatory authorisations such as FDA clearance, CE marking
or UK MHRA registration shall be read in conjunction with the full intended
use of the product:

 

The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer. The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood. The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays. The end user
is responsible for the validation of any downstream assay. The standalone
device, as indicated, does not identify, enumerate or characterize CTCs and
cannot be used to make any diagnostic/prognostic claims for CTCs, including
monitoring indications or as an aid in any disease management and/or treatment
decisions.

 

All results reported in this announcement and any other products and services
are for research use only and not for use in diagnostic procedures.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFAEEEELSESF